TY - JOUR
T1 - Prenatal growth restriction, retinal dystrophy, diabetes insipidus and white matter disease
T2 - Expanding the spectrum of PRPS1-related disorders
AU - Al-Maawali, Almundher
AU - Dupuis, Lucie
AU - Blaser, Susan
AU - Heon, Elise
AU - Tarnopolsky, Mark
AU - Al-Murshedi, Fathiya
AU - Marshall, Christian R.
AU - Paton, Tara
AU - Scherer, Stephen W.
AU - Roelofsen, Jeroen
AU - Van Kuilenburg, André B.P.
AU - Mendoza-Londono, Roberto
N1 - Funding Information:
We thank the family for their ongoing participation and patience through this difficult diagnostic journey; FORGE Canada Consortium: Finding of Rare Disease Genes in Canada; Steering Committee: Kym Boycott (leader; University of Ottawa), Jan Friedman (co-lead; University of British Columbia), Jacques Michaud (co-lead; Université de Montréal), Francois Bernier (University of Calgary), Michael Brudno (University of Toronto), Bridget Fernandez (Memorial University), Bartha Knoppers (McGill University), Mark Samuels (Université de Montréal), Steve Scherer (University of Toronto); Janet Marcadier (Clinical Coordinator) and Chandree Beaulieu (Project Manager) for their contribution to the infrastructure of the FORGE Canada Consortium. We acknowledge the contribution of the high-throughput sequencing platform of The Centre for Applied Genomics, Toronto, Canada. This manuscript is dedicated to the memory of RC. This work was funded by the Government of Canada through Genome Canada, the Canadian Institutes of Health Research and the Ontario Genomics Institute (OGI-049). Additional funding was provided by Genome Quebec, Genome British Columbia and the McLaughlin Centre.
Publisher Copyright:
© 2015 Macmillan Publishers Limited All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - PRPS1 codes for the enzyme phosphoribosyl pyrophosphate synthetase-1 (PRS-1). The spectrum of PRPS1-related disorders associated with reduced activity includes Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness (DFN2). We describe a novel phenotype associated with decreased PRS-1 function in two affected male siblings. Using whole exome and Sanger sequencing techniques, we identified a novel missense mutation in PRPS1. The clinical phenotype in our patients is characterized by high prenatal maternal α-fetoprotein, intrauterine growth restriction, dysmorphic facial features, severe intellectual disability and spastic quadraparesis. Additional phenotypic features include macular coloboma-like lesions with retinal dystrophy, severe short stature and diabetes insipidus. Exome sequencing of the two affected male siblings identified a shared putative pathogenic mutation c.586C>T p.(Arg196Trp) in the PRPS1 gene that was maternally inherited. Follow-up testing showed normal levels of hypoxanthine in urine samples and uric acid levels in blood serum. The PRS activity was significantly reduced in erythrocytes of the two patients. Nucleotide analysis in erythrocytes revealed abnormally low guanosine triphosphate and guanosine diphosphate. This presentation is the most severe form of PRPS1-deficiency syndrome described to date and expands the spectrum of PRPS1-related disorders.
AB - PRPS1 codes for the enzyme phosphoribosyl pyrophosphate synthetase-1 (PRS-1). The spectrum of PRPS1-related disorders associated with reduced activity includes Arts syndrome, Charcot-Marie-Tooth disease-5 (CMTX5) and X-linked non-syndromic sensorineural deafness (DFN2). We describe a novel phenotype associated with decreased PRS-1 function in two affected male siblings. Using whole exome and Sanger sequencing techniques, we identified a novel missense mutation in PRPS1. The clinical phenotype in our patients is characterized by high prenatal maternal α-fetoprotein, intrauterine growth restriction, dysmorphic facial features, severe intellectual disability and spastic quadraparesis. Additional phenotypic features include macular coloboma-like lesions with retinal dystrophy, severe short stature and diabetes insipidus. Exome sequencing of the two affected male siblings identified a shared putative pathogenic mutation c.586C>T p.(Arg196Trp) in the PRPS1 gene that was maternally inherited. Follow-up testing showed normal levels of hypoxanthine in urine samples and uric acid levels in blood serum. The PRS activity was significantly reduced in erythrocytes of the two patients. Nucleotide analysis in erythrocytes revealed abnormally low guanosine triphosphate and guanosine diphosphate. This presentation is the most severe form of PRPS1-deficiency syndrome described to date and expands the spectrum of PRPS1-related disorders.
UR - http://www.scopus.com/inward/record.url?scp=84931825022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84931825022&partnerID=8YFLogxK
U2 - 10.1038/ejhg.2014.112
DO - 10.1038/ejhg.2014.112
M3 - Article
C2 - 24961627
AN - SCOPUS:84931825022
SN - 1018-4813
VL - 23
SP - 310
EP - 316
JO - European Journal of Human Genetics
JF - European Journal of Human Genetics
IS - 3
ER -